(Q44407580)

2 December 2017

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival (English)

1 reference

2 December 2017

Ahmedin Jemal

1

1 reference

2 December 2017

Limin X Clegg

2

1 reference

2 December 2017

Elizabeth Ward

3

1 reference

2 December 2017

Lynn A G Ries

4

1 reference

2 December 2017

Xiaocheng Wu

5

1 reference

2 December 2017

Patricia M Jamison

6

1 reference

2 December 2017

Phyllis A Wingo

7

1 reference

2 December 2017

Holly L Howe

8

1 reference

2 December 2017

Robert N Anderson

9

1 reference

2 December 2017

Brenda K Edwards

10

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

2 December 2017

1 reference

2 December 2017

101

1 reference

2 December 2017

3-27

1 reference

2 December 2017

1

1 reference

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

2 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Impact of reporting delay and reporting error on cancer incidence rates and trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Influence of rules from the Tenth Revision of the International Classification of Diseases on U.S. cancer mortality trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Racial and ethnic disparities in the receipt of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Trends and patterns of prostate cancer: what do they suggest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

A vision for cancer incidence surveillance in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The international classification of childhood cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Permutation tests for joinpoint regression with applications to cancer rates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Screening for lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Cancer disparities by race/ethnicity and socioeconomic status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Survival of blacks and whites after a cancer diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

National practice patterns and time trends in androgen ablation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Multidisciplinary management of lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Racial differences in the treatment of early-stage lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Impact of referral patterns on the use of chemotherapy for lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Estrogen plus progestin and colorectal cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Age and adjuvant chemotherapy use after surgery for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Trends in breast cancer by race and ethnicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Adjuvant therapy for breast cancer: practice patterns of community physicians

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Racial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Special considerations in breast cancer risk and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Disparities in cancer diagnosis and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Results of radiotherapy in control of stage I and II non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Stage I-II follicular lymphoma. Treatment results for 76 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Advanced diffuse histiocytic lymphoma, a potentially curable disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Antibodies for the treatment of diffuse large cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Recent Trends in Cutaneous Melanoma Incidence Among Whites in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Update on the incidence and mortality from melanoma in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Current management of malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Race and Outcome in Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Rising incidence of renal cell cancer in the United States.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Increased incidence of serendipitously discovered renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Obesity, hypertension, and the risk of kidney cancer in men

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Childhood cancer patients' access to cooperative group cancer programs: a population-based study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

National cancer clinical trials: children have equal access; adolescents do not.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Stage at diagnosis in breast cancer: race and socioeconomic factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

The relation between health insurance coverage and clinical outcomes among women with breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Rapidly rising breast cancer incidence rates among Asian-American women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Outcomes research at the National Cancer Institute: Measuring, understanding, and improving the outcomes of cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20288

7 January 2021

Identifiers

DOI

10.1002/CNCR.20288

1 reference

2 December 2017

1 reference